Virax Biolabs Group (Virax Biolabs Group) Gross Margin % : 14.29% (As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Virax Biolabs Group's Gross Profit for the six months ended in Sep. 2023 was $0.01 Mil. Virax Biolabs Group's Revenue for the six months ended in Sep. 2023 was $0.08 Mil. Therefore, Virax Biolabs Group's Gross Margin % for the quarter that ended in Sep. 2023 was 14.29%.

The historical rank and industry rank for Virax Biolabs Group's Gross Margin % or its related term are showing as below:

VRAX' s Gross Margin % Range Over the Past 10 Years
Min: -11.11 Med: -7.26 Max: 46
Current: 12.5

During the past 4 years, the highest Gross Margin % of Virax Biolabs Group was 46.00%. The lowest was -11.11%. And the median was -7.26%.

VRAX's Gross Margin % is ranked worse than
88.86% of 736 companies
in the Biotechnology industry
Industry Median: 59.905 vs VRAX: 12.50

Virax Biolabs Group had a gross margin of 14.29% for the quarter that ended in Sep. 2023 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Virax Biolabs Group was 0.00% per year.

Virax Biolabs Group Gross Margin % Historical Data

The historical data trend for Virax Biolabs Group's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group Gross Margin % Chart

Virax Biolabs Group Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Gross Margin %

46.00

-7.26

-11.11

Virax Biolabs Group Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Gross Margin %	Get a 7-Day Free Trial			-	-	-	-33.33	14.29

Competitive Comparison of Virax Biolabs Group's Gross Margin %

For the Biotechnology subindustry, Virax Biolabs Group's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Virax Biolabs Group's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Virax Biolabs Group's Gross Margin % falls into.

Virax Biolabs Group Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Virax Biolabs Group's Gross Margin for the fiscal year that ended in Mar. 2023 is calculated as

Gross Margin % (A: Mar. 2023 )	=	Gross Profit (A: Mar. 2023 )	/	Revenue (A: Mar. 2023 )
	=	-0	/	0.009
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(0.009 - 0.01)	/	0.009
	=	-11.11 %

Virax Biolabs Group's Gross Margin for the quarter that ended in Sep. 2023 is calculated as

Gross Margin % (Q: Sep. 2023 )	=	Gross Profit (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	0	/	0.077
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(0.077 - 0.066)	/	0.077
	=	14.29 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Virax Biolabs Group (NAS:VRAX) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Virax Biolabs Group had a gross margin of 14.29% for the quarter that ended in Sep. 2023 => No sustainable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Virax Biolabs Group Gross Margin % Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Virax Biolabs Group (Virax Biolabs Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 North Audley Street, London, GBR, W1K 6LX

Website

https://www.viraxbiolabs.com

Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.